Analgesic Effect of the Synthetic Cannabinoid CT-3 on Chronic Neuropathic Pain: A Randomized Controlled Trial

JAMA

Volumn 290, Issue 13, 2003, Pages 1757-1762

  Karst, Matthias ^a   Salim, Kahlid ^a   Burstein, Sumner ^b   Conrad, Ingomar ^a   Hoy, Ludwig ^a   Schneider, Udo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJULEMIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; BUPRENORPHINE; CANNABINOID; CELECOXIB; CITALOPRAM; DIAZEPAM; DIPYRONE; DOXEPIN; FLUPIRTINE; GABAPENTIN; IMIPRAMINE; MORPHINE; NALOXONE; OXYCODONE; PLACEBO; TILIDINE; TRAMADOL; UNCLASSIFIED DRUG; ZOLPIDEM; 1',1' DIMETHYLHEPTYL DELTA(8) TETRAHYDROCANNABINOL 11 OIC ACID; 1',1'-DIMETHYLHEPTYL-DELTA(8)-TETRAHYDROCANNABINOL-11-OIC ACID; DRUG DERIVATIVE; TETRAHYDROCANNABINOL;

ADDICTION; ADULT; AGED; ALLODYNIA; ANALGESIC ACTIVITY; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; GERMANY; HUMAN; HYPERALGESIA; MALE; NEUROPATHIC PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SWEATING; VERTIGO; VISUAL ANALOG SCALE; XEROSTOMIA; CHRONIC DISEASE; MIDDLE AGED; PAIN;

ADULT; ANALGESICS, NON-NARCOTIC; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERALGESIA; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; TETRAHYDROCANNABINOL;

EID: 0141593561     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.13.1757     Document Type: Article

References (21)

1. Campbell FA, Tramèr MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? BMJ. 2001;323:1-6.
2. Burstein SH. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr Pharm Des. 2000;6:1339-1345.
3. Burstein SH, Friderichs E, Kögel B, et al. Analgesic effects of 1′,1′dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice. Life Sci. 1998;63:161-168.
4. Liu J, Li H, Burstein SH, et al. Activation and binding of peroxisome proliferator-activated receptor γ by synthetic cannabinoid ajulemic acid. Mol Pharmacol. 2003;63:983-992.
5. Bradford DT. Interpretive Reasoning and the Halstead-Reitan Tests. Brandon, Vt: Clinical Psychology Publishing Co Inc; 1992:45-46.
6. Martin WR, Sloan JD, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971;12:245-258.
7. Chait LD, Fishman MW, Schuster CR. "Hangover" effects the morning after marijuana smoking. Drug Alcohol Depend. 1985;15:229-238.
8. Hills M, Armitage P. The two-period crossover clinical trial. Br J Clin Pharmacol. 1979;8:7-20.
9. Woolf CJ, Mannion PJ. Neuropathic pain: aetiology, symptoms, mechanisms, and mangement. Lancet. 1999;353:1959-1964.
10. Weber C. NMDA-receptor antagonists in pain therapy [in German]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1998;33:475-483.
11. Martin WJ. Basic mechanisms of cannabinoid-induced analgesia. IASP Newsletter. Summer 1999:3-6.
12. Martin WJ, Loo CM, Basbaum AI. Cannabinoids are anti-allodynic in rats with persistent inflammation. Pain. 1999;82:199-205.
13. Sharpe P, Smith G. Cannabis: time for scientific evaluation of this ancient remedy? Anesth Analg. 2000;90:237-240.
14. Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975;15:139-143.
15. Noyes R Jr, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18:84-89.
16. Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgetic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci. 1990;240:1-4.
17. Tramèr MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting. BMJ. 2001;323:16-21.
18. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. 1999;83:637-649.
19. Horton AM Jr, Roberts C. Derived Trail Making Test indices in a sample of marijuana abusers: demographic effects. Int J Neurosci. 2002;112:429-438.
20. Gaudino EA, Geisler MW, Squires NK. Construct validity in the Trail Making Test: what makes part B harder? J Clin Exp Neuropsychol. 1995;17:529-535.
21. Wachtel SR, El Sohly MA, Ross SA, et al. Comparison of the subjective effects of delta-9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology. 2002;161:331-339.